Form 8-K · Current report
Illumina, Inc. 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0001110803
- Accession no.
- 0001110803-26-000155
Summary
Illumina reported second-quarter fiscal 2026 revenue of $1.16 billion, up 9.5% from a year earlier, with GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31, and raised its full-year 2026 revenue and earnings guidance. CEO Jacob Thaysen attributed the results to clinical customers expanding sequencing-intensive applications and continued demand for NovaSeq X.
Key points
- Q2 2026 revenue was $1.159 billion versus $1.059 billion in Q2 2025, a 9.5% increase; rest-of-world organic growth was 8.1%.
- GAAP operating margin was 21.1% and non-GAAP operating margin 22.5%; free cash flow was $162 million, with $1.17 billion in cash, cash equivalents and short-term investments at quarter end.
- Full-year 2026 guidance was raised to total revenue of $4.60-$4.64 billion from $4.52-$4.62 billion and non-GAAP diluted EPS of $5.30-$5.40 from $5.15-$5.30, with rest-of-world organic growth now expected above 5% versus 2%-4% previously.
- The quarter ended June 28, 2026, and the release was signed by Chief Financial Officer Ankur Dhingra.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition Item 9.01 Financial Statements and Exhibits SIGNATURES Exhibit Index Table of Contents Item 2.02 Results of Operations and Financial Condition. On July 30, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the second quarter ended June 28, 2026. The full text of the Company’s press release is attached hereto as Exhibit 99.1. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.